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Dxclusion with fenestration and a systemic-to-pulmonary
hunt. This surgical strategy has provided effective pallia-
ion for a group of patients that has historically had poor
utcomes. For severe cases of Ebstein anomaly with asso-
iated left heart obstructive defects, transplantation should
e considered.
imitations
lthough this is a relatively large series dealing with sur-
ical intervention for neonates with Ebstein malformation
resenting in a fulminate manner, the total number of pa-
ients is small and the power of the study is therefore
ffected. Additionally, the RV exclusion technique devel-
ped in a stepwise fashion, which did not allow for ran-
omization to better elucidate the difference between pa-
ients with and without fenestration. Finally, we recognize
hat we may use the RV exclusion technique more readily
ecause of our institutional experience and outcomes.
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iscussion
r Christopher J. Knott-Craig (Oklahoma City, Okla). I rise to
ongratulate you on the first major presentation on patients with
eonatal Ebstein anomaly and on the continued results that you h
The Journal of Thoracicave shared with us. In your presentation you review a 14-year
xperience with 16 patients, most of whom underwent RV exclu-
ion and have excellent outcomes based on historical norms.
We also have a good experience with neonatal Ebstein patients,
aving had the opportunity to operate on 22 of these patients over
2 years; we have taken a different approach in that we have
ttempted a 2-ventricle repair in all of them with a greater than
0% survival.
Clearly, there is room to do an RV exclusion operation and
here is room to do a 2-ventricle repair. The dilemma that we face
s surgeons is trying to stratify which patients would do better with
ne operation versus the other. Can you help us make a decision
ased on your experience? Do you have any insights that you
ould share with us based on your most recent experience in this
egard?
Dr Reemtsen. I think the million-dollar question is, when
hould this be done? We think of the RV exclusion as more of a
ool to deal with Ebstein anomaly than as an answer. If the valve
issue looks good and we think we can approach a repair and there
s a tripartite ventricle with an open RVOT, then we absolutely will
ttempt to repair the malformation. If we are not able to do, by
chocardiogram, an adequate repair, we would do an RV exclusion
t that point.
I think the more difficult group is the one in which there is
ailure at delamination, there is really no identifiable leaflet tissue,
nd there is an obstructed RVOT. I do not think, at least in our
ands, that we can get an adequate repair as well as we have now.
e have to open up the RVOT with a small homograft, and we all
now the implications of that.
Trying to see whether there is a usable ventricle is our main
oal, as well as valve tissue that will give us a repair that would be
ess than mild, mild or less, on an echocardiogram.
Dr Knott-Craig. One may argue that if you do a very aggres-
ive tricuspid valve annuloplasty and have a regurgitant valve at
he end, you may, at least physiologically, have pretty much the
ame results as if you sew a patch of tissue to the tricuspid valve
nnulus and fenestrate it. I think ultimately the two end points may
ot be very dissimilar, at least in a certain group of patients.
Could you tell us a little bit about the patient in whom a heart
ransplant was performed? How did you decide on transplantation
or that patient in contradistinction to the other patients?
Dr Reemtsen. This patient was the only one who had really
evere left-sided malformations, had hypoplasia of the mitral valve
elatively, and had moderate valve regurgitation in association
ith a coarctation. We believed that surgery would be high risk in
his patient, who had a univentricular heart with the only valve
eing the mitral valve, so we listed that patient as soon as we
ould.
Dr Knott-Craig. My final question relates to your entire cohort
f patients. Is it possible that some of these patients might not need
n operation in the early postpartum period? How did you differ-
ntiate between these and the really sick neonates? How did you
tabilized them in the preoperative period?
Dr Reemtsen. We didn’t stabilize them. Essentially, the pa-
ients that we operated on had not responded to medical therapy. I
now that there is a movement now to incorporate nitric oxide and
ry to get these patients out of the neonatal period, but we do not
ave a lot of experience with that approach. I think if that is able
and Cardiovascular Surgery ● Volume 132, Number 6 1289
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Do happen, that would be preferable to operating on these patients
n the neonatal period. However, the overwhelming majority of
hese patients were receiving maximal support. We are trying not
o operate. Our goal is not to operate on them as neonates, but
hese patients forced our hand.
Dr Knott-Craig. In this regard, were there any neonates with
bstein anomaly treated at your institution who did not have
urgery during the neonatal period?
Dr Reemtsen. I really can’t comment on that, I’m sorry. I don’t
ave that data.
Dr Starnes. Yes, we have had patients come to our unit and
tabilized on prostaglandin and sometimes nitric oxide. We fol-
owed those patients and they have been able to go home. We had
ne as recently as 6 months ago. We do not arbitrarily operate on
veryone who comes into the unit; we try to stabilize them. As
rian was saying, we try to make sure that we have a group of
atients in whom medical therapy failed before we surgically
ntervene. A lot of these patients get in trouble with acidosis. We
ust cannot stabilize them and so we are forced to take them to the
perating room.
Dr Carl L. Backer (Chicago, Ill). Before the next question, I
ant to poll the audience. We had a nice presentation from Chris
nott-Craig yesterday and now the Starnes approach today. Given
very sick neonate who is cyanotic and has an x-ray film that
ooks like that, of the congenital heart surgeons here, how many
ould try to repair that valve the way Chris described? [Show of
ands.] It looks like a handful. How many would opt for the
tarnes approach and go to the functional single ventricle? [Show
f hands.] It looks like it’s about 30% for repair and about 60% for
onversion to single ventricle.
Dr Shunji Sano (Okayama City, Japan). I always respect Dr
tarnes’, and also his colleagues’, challenge to the complex anom-
lies. You may know that we presented our experience with
bstein anomaly in the neonate and small infant at this meeting in
000.
The major difference of our approach from your operation is
xcision of the RV free wall to reduce the size of the RV and the
ight atrium. Immediately postoperatively, the cardiothoracic ratio
s reduced to 0.52. Also, the LV ejection fraction is increased from
7% to 62% and the cardiac index from 2.1 to 3.5. It is mostly due
nly to a change in the shape of the intraventricular septum.
My question is this: is there any patient who may survive after
he operation if the cardiothoracic ratio will reduce the size from
.08 to less than 0.6 and also if the left ventricular function is
mproved?
Dr Reemtsen. I wish I was shown an x-ray film, actually. Our
xperience, especially with fenestration after RV exclusion, is that
he patients do not go back to a normal cardiac silhouette; rather,
t is extremely reduced. w
290 The Journal of Thoracic and Cardiovascular Surgery ● DecWith the fenestration, I do not think that a ventricular plication
s necessary. In fact, I think you obviously risk injury to the right
oronary artery, which would be devastating.
Regarding your comment on left ventricular function, I do not
ave the exact data on that. However, I have observed that the
entricular function will return to near normal after decompression
f the right side of the heart. We do downsize the right atrium, and
think that has a large part to do with it.
As for an RVOT obstruction, I would be hesitant, especially in
his subgroup, to do an excision in that area. This is a group of
atients that, as you know, has a high risk for dysrhythmia post-
peratively, and incision in the heart may carry a risk.
Secondarily, if you make the PA, the RVOT, somehow regur-
itant in this patient population, even with the fenestration, that
isrupts the entire physiology that you have created. So I think if
here is any regurgitation, you really have to interrupt the PA at
hat point.
Dr Sano. In our series, since we changed to this approach, we
ave no early or late deaths. Also, we do the fenestration as in the
tarnes procedure. If the pulmonary valve is incompetent, we close
he pulmonary valve.
Dr Joseph A. Dearani (Rochester, Minn). My question is a
ittle bit along the lines of Dr Sano; maybe you have already
nswered it. In any of the patients who were managed with a
ingle-ventricle pathway, was it necessary to resect or reduce the
ize of the RV at the time of the Glenn or Fontan procedure? If not,
hat would be your indications to do that?
Dr Reemtsen. The plication, I think, was performed early on,
ind of at the same time as the nonfenestration. There were
ttempts at doing some ventricular plications; however, this hap-
ened in only 3 patients, so I really cannot give you a realistic or
n accurate answer on whether those patients have done better or
orse. However, none of the last 8 consecutive patients who
nderwent the Starnes procedure had ventricular plication. I think
ith the way the physiology is set up, that is becoming a move that
e actually do not need to do.
Dr Scott M. Bradley (Charleston, SC). And that includes later,
t the time of the Glenn or the Fontan procedure?
Dr Reemtsen. We have not modified it at all at the time of the
ontan or Glenn procedure.
Dr Starnes. What we have seen in late follow-up is that most
f these ventricles actually become quite a bit smaller in size. They
end to involute, if you would. At the time of a bidirectional Glenn
r Fontan procedure, they are about half the size they were, or you
ould expect them to be, at the time of operation. They have not
ontinued to increase in size or enlarge over that period of time, so
e have been pleasantly surprised by that.
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